Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2013 Apr 15;257(1-2):7-12. doi: 10.1016/j.jneuroim.2013.01.005. Epub 2013 Feb 4.

Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1.

Author information

  • 1Faculty of Life Sciences, The University of Manchester, Manchester, M13 9PT, UK.

Abstract

Intravenous immunoglobulin (IVIG) treatment of Alzheimer's disease (AD) has been encouraging. Its mechanism of action might be via anti-β-amyloid (Aβ) antibodies which facilitate Aβ clearance. However, IVIG's benefits might result from its antiviral activity, particularly against herpes simplex virus type 1 (HSV1), a virus implicated in AD. We investigated IVIG's effect on HSV1, specifically on the accumulation of Aβ and abnormally phosphorylated tau which it causes. We show that IVIG is effective at reducing the accumulation of these abnormal molecules and that it acts synergistically with the antiviral acyclovir, suggesting that their combined use would be beneficial for treating AD.

PMID:
23385080
DOI:
10.1016/j.jneuroim.2013.01.005
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center